Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Current Liabilities (2016 - 2025)

Voyager Therapeutics' Total Current Liabilities history spans 11 years, with the latest figure at $26.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 46.69% year-over-year to $26.5 million; the TTM value through Dec 2025 reached $26.5 million, down 46.69%, while the annual FY2025 figure was $26.5 million, 46.69% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $26.5 million at Voyager Therapeutics, down from $35.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $101.7 million in Q1 2022 and bottomed at $19.9 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $44.8 million (2023), against an average of $50.8 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 310.8% in 2022 before it crashed 80.39% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $51.0 million in 2021, then skyrocketed by 42.39% to $72.6 million in 2022, then fell by 11.13% to $64.5 million in 2023, then decreased by 22.82% to $49.8 million in 2024, then plummeted by 46.69% to $26.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Total Current Liabilities are $26.5 million (Q4 2025), $35.5 million (Q3 2025), and $42.0 million (Q2 2025).